Phaseline

Companies › CrystalGenomics

CrystalGenomics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Camrelizumab (SHR-1210)
Programmed cell death protein 1 antagonist
PDCD1Phase 2Non Squamous Non Small Cell Lung CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05841472Camrelizumab (SHR-1210)Phase 2Non Squamous Non Small Cell Lung CancerOncologyDec 2026

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Companies built like this

Taizhou Hanzhong biomedical Agenus Partner Therapeutics STCube Ambrx

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.